SELB Selecta Biosciences Inc.

9.95
-0.18  -2%
Previous Close 10.13
Open 10.10
Price To book 3.42
Market Cap 222304773
Shares 22,336,576
Volume 49,153
Short Ratio 11.60
Av. Daily Volume 237,546

SEC filingsSee all SEC filings

  1. 8-K - Current report 171198324
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181191
  3. 8-K - Current report 171181180
  4. 8-K - Current report 171157152
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171112082

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing commenced late October 2016. Initial data released at EULAR June 15, 2017. Updated data presented November 7, 2017. Phase 3 planned for 2018.
SEL-212
Tophaceous gout

Latest News

  1. Selecta Biosciences to Webcast Investor Conference Presentations This Week
  2. Edited Transcript of SELB earnings conference call or presentation 7-Nov-17 1:30pm GMT
  3. Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
  4. Selecta Biosciences, Inc. to Host Earnings Call
  5. Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
  6. Selecta Biosciences Announces Important Additions to Senior Leadership Team
  7. Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations
  8. Selecta Biosciences to Participate in Upcoming Investor Conferences
  9. Selecta Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : SELB-US : September 13, 2017
  10. Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : September 1, 2017
  11. Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  12. Selecta Biosciences, Inc. – Value Analysis (NASDAQ:SELB) : August 15, 2017
  13. Edited Transcript of SELB earnings conference call or presentation 11-Aug-17 12:30pm GMT
  14. Selecta Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : SELB-US : August 1, 2017
  15. Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher

SEC Filings

  1. 8-K - Current report 171198324
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181191
  3. 8-K - Current report 171181180
  4. 8-K - Current report 171157152
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171112082
  6. 8-K - Current report 171083679
  7. EFFECT - Notice of Effectiveness 171055994
  8. CORRESP [Cover] - Correspondence
  9. CT ORDER - Confidential treatment order 171046488
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171034510